Pitango HealthTech, Pitango VC’s dedicated healthcare fund, launched its second dedicated healthcare fund, Pitango HealthTech II.
Pitango HealthTech II had its first closing of the new $175M fund dedicated to investing in entrepreneurs leveraging data science, AI, medical devices and novel biology at the forefront of the transformation of healthcare.
Led by Ittai Harel (Managing Partner), Hila Karah (Managing Partner), Dr. Jonathan Glazer (Partner), Joel Schoppig (Senior Principal) and Dr. Seth Rudnick (Special Advisor), the fund invests in healthcare innovation, including the decentralization of healthcare, personalized medicine, medical devices and diagnostics, as well as artificial intelligence, software and data infrastructure, backing companies from seed to commercial stage.
The first investments of the newest fund include:
- QuantHealth.ai, an AI company focused on clinical trial simulations to accelerate and de-risk drug development, and
- Nevia Bio, a FemTech company developing an AI-based biomarker platform for early detection of women’s health diseases.
Pitango HealthTech investors combine clinical and operational experience with nearly three decades of investing in over 50 healthcare companies, with 15 successful exits. Previous investments include companies such as Protai, Laguna Health, Vertos, Visby, Clew and Magenta.
Pitango HealthTech is part of the Pitango investment platform, operating alongside Pitango First and Pitango Growth Funds. Since its inception in 1993, the Herzliya, Israel-based firm has invested in over 250 companies and seen more than 85 become publicly traded companies, or acquired by strategic players.